Home Capital Broker's Calls

Phillip Securities initiates 'buy' for iX Biopharma on prospect of turning profitable in FY21

Jeffrey Tan
Jeffrey Tan10/2/2020 12:11 PM GMT+08  • 1 min read
Phillip Securities initiates 'buy' for iX Biopharma on prospect of turning profitable in FY21
The biotech company could finally turn profitable in FY21 as revenue could be bumped up by as much as 250%, says the brokerage.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Phillip Securities has initiated coverage on iX Biopharma with a “buy” recommendation and target price of 45.5 cents.

This comes as the brokerage believes the biotech company could finally turn profitable in FY21 as its revenue could be bumped up by as much as 250%.

It notes that iX Biopharma has started to commercialise its WaferiX subligual delivery of drugs as the company plans to expand capacity.

×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.